Bill > SB353

This bill modifies Montana's Right to Try Act to specifically address the use of investigational drugs, biological products, or devices for minors with terminal illnesses. Currently, patients seeking experimental treatments must meet four criteria: have exhausted all FDA-approved treatment options, receive a recommendation from their healthcare provider, provide written informed consent, and have documentation confirming they meet the requirements. The key change is the addition of a new provision that limits a minor's access to such investigational treatments, allowing them only if the minor has a terminal illness as attested by their treating healthcare provider. This means that while adult patients can more readily access experimental treatments under the Right to Try Act, minors face additional restrictions and must have a terminal diagnosis to be considered eligible. The bill aims to provide a more cautious approach to experimental medical treatments for minors, balancing potential medical innovation with patient safety concerns specific to underage patients.